Featured Research

from universities, journals, and other organizations

Researchers find MK1775 active against sarcomas

Date:
December 7, 2011
Source:
H. Lee Moffitt Cancer Center & Research Institute
Summary:
MK1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas. This finding suggests that a badly needed new agent against sarcomas -- especially sarcomas affecting children -- may be at hand.

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas -- especially sarcomas affecting children -- may be at hand.

According to corresponding author Soner Altiok, M.D., Ph.D., sarcomas are rare forms of cancers and are composed of more than 70 types. Approximately 10 percent of children with cancer are diagnosed with sarcomas, compared to eight percent of young adults and one percent of adults. While chemotherapy and radiation play a role in treating some sarcoma patients, escalations of treatment are unlikely to be tolerable, nor will they prolong survival, said the researchers.

"There is a great need for new agents to treat sarcomas and improve patient outcomes," said Altiok. "Toxicity from radiation and chemotherapy is high and response rates for patients with sarcomas are modest, with improvement and survival negligible."

Sarcomas are cancers that result from transformed cells in one of a number of tissues that develop from embryonic mesoderm. Sarcomas include tumors of bone, cartilage, fat, muscle, vascular and hematopoetic tissues. Sarcomas are different from carcinomas that originate in epithelial cells and result in more common cancers, such as breast, colon and lung cancers.

Researchers from Moffitt's Experimental Therapeutics Program and the Sarcoma Program collaborated in testing MK1775's ability to inhibit Wee1, a nuclear kinase known to be a regulator of cell size and an initiator of cell division, or mitosis. Wee1 is known to play a role in determining the timepoint at which mitosis begins. Loss of Wee1 can produce smaller than normal daughter cells. The researchers hypothesized that inhibition of Wee1 could also induce apoptosis, or programmed cell death in sarcoma tumors.

"Inhibition of the pathways critical to tumor cell survival by molecularly targeted therapy represents an opportunity to reverse the biological basis of tumor formation," explained Altiok. "We found that MK1775 treatment induces apoptopic cell death in four sarcoma cell lines at clinically relevant doses."

To further prove that inhibition of Wee1 by MK1775 leads to mitotic cell death in sarcomas cells, the researchers performed additional studies, including studies on sarcomas related to mutations, such as with the p53 gene. They also showed that MK1775 was an active inhibitor of Wee1 regardless of the p53 mutation status of the tumors in the cell lines tested.

"The cytotoxic effect of Wee1 inhibition on sarcoma cells appears to be independent of p53 mutation status following our testing sarcoma cell lines with different p53 mutations," he said. "All of them were highly sensitive to MK1775, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas."

The researchers concluded that their laboratory tests on sarcoma cell lines suggest that MK1775 is effective as a monotherapy even in the cell lines that include p53 wild, p53 null and p53 mutant statuses.

Other studies have shown that MK1775 is a well-tolerated drug. No toxicity dose limit has been established, making MK 1775 a potential therapeutic agent for treating both adult and pediatric sarcoma patients.

"Our data has shown that MK1775 treatment causes cell death suggesting 'mitotic catastrophe,' a type of cell death that occurs during cell mitosis," concluded Altiok.


Story Source:

The above story is based on materials provided by H. Lee Moffitt Cancer Center & Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. M. Kreahling, J. Gemmer, D. Reed, G. D. Letson, M. M. Bui, S. Altiok. MK1775, A Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity Against Sarcoma Cells. Molecular Cancer Therapeutics, 2011; DOI: 10.1158/1535-7163.MCT-11-0529

Cite This Page:

H. Lee Moffitt Cancer Center & Research Institute. "Researchers find MK1775 active against sarcomas." ScienceDaily. ScienceDaily, 7 December 2011. <www.sciencedaily.com/releases/2011/12/111202155748.htm>.
H. Lee Moffitt Cancer Center & Research Institute. (2011, December 7). Researchers find MK1775 active against sarcomas. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2011/12/111202155748.htm
H. Lee Moffitt Cancer Center & Research Institute. "Researchers find MK1775 active against sarcomas." ScienceDaily. www.sciencedaily.com/releases/2011/12/111202155748.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins